Ascendis Pharma A-S

Yahoo Finance • 4 days ago

Ascendis Pharma to List Ordinary Shares Directly on Nasdaq

Ascendis Pharma - Ordinary shares expected to commence trading on Nasdaq on April 20, 2026 following exchange of all American Depositary Shares (ADSs) - ADS holders will receive one ordinary share listed on Nasdaq for each ADS held - Si... Full story

Yahoo Finance • 4 days ago

New Data from Week 52 of the Ongoing COACH Trial Showed that TransCon® hGH Accelerated TransCon® CNP’s Benefits Beyond Linear Growth in Children with Achondroplasia

- Unprecedented improvements in arm span observed with TransCon CNP and TransCon hGH combination therapy, a measure highly meaningful to the achondroplasia community - Enhanced improvements in spinal canal dimensions observed with TransCo... Full story

Yahoo Finance • 6 days ago

Ascendis Receives Orphan Drug Exclusivity and Launches YUVIWEL® (Navepegritide) in the United States

- YUVIWEL was granted orphan drug exclusivity by U.S. FDA to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses - YUVIWEL is now commercially available in the U.S. with revenue no... Full story

Yahoo Finance • 8 days ago

Ascendis Pharma A/S (ASND) Reports Positive Week 52 Data from Phase 2 New InsiGHTS Trial

Ascendis Pharma A/S (NASDAQ:ASND) is one of the 7 Fastest Growing European Stocks to Invest In. On March 17, 2026, Ascendis Pharma A/S (NASDAQ:ASND) announced positive Week 52 topline results from the Phase 2 New InsiGHTS trial evaluating... Full story

Yahoo Finance • last month

Ascendis Wins FDA Approval For Rare Disease Therapy

Ascendis Pharma A/S shares are up during Monday’s premarket session following the FDA’s approval of Yuviwel (navepegritide; developed as TransCon CNP), the first and only once-weekly treatment for children with achondroplasia. FDA Approva... Full story

Yahoo Finance • last month

FDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and Older

The first and only approved achondroplasia therapy to provide continuous systemic exposure to CNP over the weekly dosing intervalCommercial availability expected during early part of Q2 2026Rare Pediatric Disease Priority Review Voucher gr... Full story

Yahoo Finance • 2 months ago

Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Million

On February 17, 2026, Perceptive Advisors disclosed a significant buy of 431,432 shares of Praxis Precision Medicines(NASDAQ:PRAX), with an estimated transaction value of $80.34 million based on quarterly average pricing, according to its... Full story

Yahoo Finance • 2 months ago

Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position

On February 17, 2026, Perceptive Advisors reported a buy of Celcuity(NASDAQ:CELC), adding 203,881 shares in the fourth quarter, with an estimated transaction value of $16.76 million based on quarterly average pricing. What happened Accor... Full story

Yahoo Finance • 2 months ago

Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction

On February 17, 2026, Perceptive Advisors disclosed a buy of 978,662 shares of Apogee Therapeutics(NASDAQ:APGE), with an estimated transaction value of $61.64 million based on quarterly average pricing. What happened According to a Febru... Full story

Yahoo Finance • 2 months ago

Ascendis Pharma (ASND) Revenue Nearly Doubles to €720M in 2025 Fueled by Core Product Growth

Ascendis Pharma (NASDAQ:ASND) is one of the best NASDAQ growth stocks to buy for the next 2 years. On February 11, Ascendis Pharma reported that it nearly doubled its total revenue for 2025 to €720 million, fueled by the rapid global adopt... Full story

Yahoo Finance • 2 months ago

Liberty All-Star® Growth Fund, Inc. January 2026 Monthly Update

BOSTON, February 14, 2026--(BUSINESS WIRE)--Below is the January 2026 Monthly Update for the Liberty All-Star Growth Fund, Inc. (NYSE: ASG). Liberty All-Star Growth Fund, Inc. Ticker: ASG Monthly Update, January 2026 Investment Approach... Full story

Yahoo Finance • 2 months ago

Ascendis Pharma Reports Fourth Quarter and Full-Year 2025 Financial Results

Q4 2025 product revenue of €240 million and FY 2025 product revenue of €684 millionQ4 2025 operating profit of €10 million and cash flow from operating activities of €73 millionTransCon® CNP under FDA Priority Review, PDUFA action goal dat... Full story

Yahoo Finance • 4 months ago

Vanguard Health Care Fund's Strategic Moves: Spotlight on AbbVie Inc

This article first appeared on GuruFocus. Exploring the Fund's Recent Portfolio Adjustments Vanguard Health Care Fund (Trades, Portfolio) recently submitted its N-PORT filing for the third quarter of 2025, shedding light on its strategic... Full story

Yahoo Finance • 4 months ago

Liberty All-Star® Growth Fund, Inc. November 2025 Monthly Update

BOSTON, December 15, 2025--(BUSINESS WIRE)--Below is the November 2025 Monthly Update for the Liberty All-Star Growth Fund, Inc. (NYSE: ASG). Liberty All-Star Growth Fund, Inc. Ticker: ASG Monthly Update, November 2025 Investment Approa... Full story

Yahoo Finance • 4 months ago

The Biotech Industry Is Healthier Than Investors Think. These Are the Stocks to Watch.

RA Capital Management’s Peter Kolchinsky says the companies that survived the industry’s 2021 rout are thriving—and looking to make deals. Continue Reading... Full story

Yahoo Finance • 4 months ago

European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading

European equities traded in the US as American depositary receipts were little changed late Thursday PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 4 months ago

Former Novo Nordisk Executive Jesper Høiland Joins Alva Therapeutics' Board of Directors

MILPITAS, Calif., Dec. 3, 2025 /PRNewswire/ -- Alva Therapeutics, Inc. ("Alva") a company developing a novel oral incretin secretagogue based therapy for the treatment of Type 2 diabetes and obesity—announced that Mr. Jesper Høiland has be... Full story

Yahoo Finance • 4 months ago

Ascendis dwarfism drug candidate review extended by FDA

[FDA headquarters in Washington DC.] JHVEPhoto * The US FDA has extended the review time of an NDA for Ascendis Pharma's (ASND [https://seekingalpha.com/symbol/ASND]) TransCon CNP (navepegritide), a treatment for children with achondrop... Full story

Yahoo Finance • 5 months ago

European Equities Traded in the US as American Depositary Receipts Surge in Wednesday Trading

European equities traded in the US as American depositary receipts were surging higher late Wednesda PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 5 months ago

Ascendis Announces Extension of FDA Review Period for TransCon CNP (navepegritide) for Children with Achondroplasia

–  Prescription Drug User Fee Act (PDUFA) goal date extended by three months to February 28, 2026 COPENHAGEN, Denmark, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the U.S. Food & Drug Admini... Full story